Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ADAPT-NK + bispecific NK cell engager targeting BCMA
- Development stage
- Preclinical
- Lead developer
- Sanofi
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
**ADAPT-NK + bispecific NK cell engager targeting BCMA** is a combination immunotherapy for multiple myeloma consisting of ex vivo expanded adaptive NK cells and an affibody-derived bispecific NK cell engager that simultaneously binds CD16a on NK cells and B-cell maturation antigen (BCMA) on tumor cells. The bispecific engager redirects and activates NK cells to enhance cytotoxicity against BCMA-expressing plasma cells, potentially offering improved antitumor efficacy with reduced proinflammatory cytokine production compared to T-cell engagers. This approach leverages adaptive NK cells, which exhibit enhanced memory-like properties, in combination with the engager to boost NK cell persistence and tumor killing in relapsed/refractory multiple myeloma.[2]
- Other names
- adaptive NK cells + BCMA bispecific NK cell engager
02
Targets
FCGR3A (Low affinity immunoglobulin gamma Fc region receptor III-A)BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on ADAPT-NK + bispecific NK cell engager targeting BCMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ADAPT-NK + bispecific NK cell engager targeting BCMA.